Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736499 | 0.98 | ESR1 (0.32) | KDM4ELMNAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL15495344 | 0.73 | QDPR (0.35) | KDM4ELMNAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL15632339 | 0.64 | BAD (0.42) | KDM4ELMNAMAPTESR1TRPA1 | |
| SCHEMBL15632277 | 0.61 | KDM4E (0.39) | KDM4ELMNAMAPTSMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8600472 | 0.60 | — | — | |
| SCHEMBL1277062 | 0.57 | — | — | |
| SCHEMBL27750347 | 0.56 | ALDH1A1 (0.38) | KDM4EMAPTESR1TRPA1TP53 | |
| SCHEMBL361051 | 0.55 | PIM1 (0.41) | KDM4ELMNAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL68013 | 0.55 | TRPA1 (0.53) | KDM4ELMNAMAPTESR1TRPA1 | |
| SCHEMBL29457565 | 0.55 | TRPA1 (0.53) | KDM4ELMNAMAPTESR1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | TADA YUKIO | 2006-03-09 | — | — | US | disclosed |
| US-6977266-B2 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1357111-A1 | PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | KDM4E 1679/4885LMNA 3511/4885MAPT 4074/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | KDM4E 2840/4885LMNA 4521/4885MAPT 3869/4885 |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | CNR2, CNR1, NPY2R | KDM4E 1228/4885LMNA 2831/4885MAPT 4248/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | KDM4E 3245/4885LMNA 4604/4885MAPT 3393/4885 |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | CNR1, CNR2, NPY1R | KDM4E 590/4885LMNA 2809/4885MAPT 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.